Peptide-based vaccination for colorectal cancer

Expert Opinion on Biological Therapy

Volumn 5, Issue 6, 2005, Pages 799-807

  Tsuruma, Tetsuhiro ^a   Hata, Fumitake ^a   Furuhata, Tomohisa ^a   Ohmura, Tosei ^a   Katsuramaki, Tadashi ^a   Yamaguchi, Koji ^a   Kimura, Yasutoshi ^a   Torigoe, Toshihiko ^a   Sato, Noriyuki ^a   Hirata, Koichi ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Colorectal cancer; Immunotherapy; Peptide; Vaccine

Indexed keywords

ADJUVANT; BCG VACCINE; CANCER VACCINE; CHORIONIC GONADOTROPIN BETA SUBUNIT; CTLP ORIENTED PEPTIDE VACCINE; CYCLOPHOSPHAMIDE; DIPHTHERIA TOXOID; FREUND ADJUVANT; MUCIN 1; PEPTIDE; RECOMBINANT EPIDERMAL GROWTH FACTOR; SART 3 109 118; SART 3 315 323; SART 3 [109-118]; SART 3 [315-323]; SQUAMOUS CELL CARCINOMA ANTIGEN; SURVIVIN; SURVIVIN 2B; TETANUS TOXOID; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BONE PAIN; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; DIARRHEA; DIZZINESS; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPERCALCEMIA; HYPOALBUMINEMIA; IMMUNE RESPONSE; IMMUNOTHERAPY; INJECTION SITE REACTION; MALAISE; METASTASIS; MYALGIA; NAUSEA; NIGHT SWEAT; PROGNOSIS; REVIEW; RIGOR; VACCINATION; VOMITING;

ADJUVANTS, IMMUNOLOGIC; CANCER VACCINES; CLINICAL TRIALS; COLORECTAL NEOPLASMS; DRUG MONITORING; FORECASTING; HUMANS; T-LYMPHOCYTES; VACCINES, SUBUNIT;

EID: 21044443147     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.6.799     Document Type: Review

References (50)

1. ARBER N, LEVIN B: Chemoprevention of colorectal cancer: ready for routine use? Recent Results Cancer Res. (2005) 166:213-230.
2. ZANIBONI A, LABIANCA R: Adjuvant therapy for stage II colon cancer: an elephant in the living room? Ann. Oncol. (2004) 15:1310-1318.
3. COUTINHO AK, ROCHA LIMA CM: Metastatic colorectal cancer systemic treatment in the new millennium. Cancer Control (2003) 10:224-238.
4. FOON KA, YANNELLI J, BHATTACHARYA-CHATTERJEE M: Colorectal cancer as a model for immunotherapy. Clin. Cancer Res. ( 1999) 5:225-236.
5. BANCHEREAU J, BRIERE F, CAUX C et al.: Immunobiology of dendritic cells. Annu. Rev. Immunol. (2000) 18:767-811.
6. STEINMAN RM: The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. (1991) 9:271-296.
7. ALLISON JP, HURWITZ AA, LEACH DR: Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr. Opin. Immunol. (1995) 7:682-686.
8. GRETEN TF, JAFFEE EM: Cancer vaccines. J. Clin. Oncol. (1999) 17:1047-1060.
9. ROCK KL, GAMBLE S, ROTHSTEIN L: Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science (1990) 249:918-921.
10. GRANT EP, ROCK KL: MHC class I-restricted presentation of exogenous antigen by thymic antigen-presenting cells in vitro and in vivo. J. Immunol. (1992) 148:13-18.
11. ROCK KL, ROTHSTEIN L, GAMBLE S, FLEISCHACKER C: Characterization of antigen-presenting cells that present exogenous antigens in association with class I MHC molecules. J. Immunol. (1993) 150:438-446.
12. HARDING CV, SONG R: Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J. Immunol. (1994) 153:4925-4933.
13. KOVACSOVIC-BANKOWSKI M, ROCK KL: A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science (1995) 267:243-245.
14. TAMURA Y, KUROTAKI T, IMAI A, TORIGOE T, SATO N: Exogenous HSP90-peptide complexes-loaded dendritic cells elicit crosspresentation to cytotoxic T lymphocytes: application for cancer vaccine. 19th International Society for Biological Therapy of Cancer. San Francisco, USA (5-7 November 2004).
15. SWAIN SL, BRADLEY LM, CROFT M et al.: Helper T-cell subsets: phenotype, function and the role of lymphokines in regulating their development. Immunol. Rev. (1991) 123:115-144.
16. MACKAY CR: Immunological memory. Adv. Immunol. (1993) 53:217-265.
17. JAGER E, RINGHOFFER M, DIENES HP et al.: Granulocyte-macrophage-colony- stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int. J. Cancer (1996) 67:54-62.
18. MURRAY JL, GILLOGLY ME, PRZEPIORKA D et al.: Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2 patients with metastatic breast and ovarian cancer. Clin. Cancer Res. (2002) 8:3407-3418.
19. TORIGOE T, TSURUMA T, SHIJYUBOU N et al.: Phase I clinical study assessing survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal, breast or lung cancer. 19th International Society for Biological Therapy of Cancer. San Francisco, USA (5-7 November 2004).
20. TSURUMA T, HATA F, TORIGOE T et al.: Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J. Transl. Med. (2004) 2:19-29. Clinical trial of peptide vaccine therapy for patients with colorectal cancer.
21. KUROTAKI T, TAMURA Y, HIRATA K, SATO N: Effective induction of CTLs by immunization with HSP90-cancer peptide complex. 19th International Society for Biological Therapy of Cancer. San Francisco, USA (5-7 November 2004). Investigation of immunisation with hsp90-cancer peptide complex, which induced the cytotoxicity of CTLs.
22. MAZZAFERRO V, COPPA J, CARRABBA MG et al.: Vaccination with autologous tumor-derived heat-shock protein Gp96 after liver resection for metastatic colorectal cancer. Clin. Cancer Res. (2003) 9:3235-3245. A clinical trial that was carried out using autologous tumour-derived HSPPC-96 to vaccinate patients after resection of liver metastases of colorectal carcinoma.
23. SHANG XY, CHEN HS, ZHANG HG et al.: The spontaneous CD8 T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients. Clin. Cancer Res. (2004) 10:6945-6955.
24. HOBEIKA AC, MORSE MA, OSADA T et al.: Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC tetramer, ELISpot, and intracellular cytokine analysis. J. Immunother. (2005) 28:63-72. Investigation of antigen-specific T cell responses: peptide/MHC tetramer analysis, ELISPOT assay and intracellular cytokine flow cytometry analysis.
25. WHITESIDE TL, ZHAO Y, TSUKISHIRO T, ELDER EM, GOODING W, BAAR J: Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma. Clin. Cancer Res. (2003) 9:641-649. Investigation of antigen-specific T cell responses: peptide/MHC tetramer analysis, ELISPOT assay and intracellular cytokine flow cytometry analysis.
26. MARCHAND M, VAN BAREN N, WEYNANTS P et al.: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer (1999) 80:219-230.
27. CLEMENTE CG, MIHM MC JR, BUFALINO R, ZURRIDA S, COLLINI P, CASCINELLI N: Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer (1996) 77:1303-1310.
28. DUNBAR PR, SMITH CL, CHAO D et al.: A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J. Immunol. (2000) 165:6644-6652.
29. ROMERO P, DUNBAR PR, VALMORI D et al.: Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced rumor-specific cytolytic T lymphocytes. J. Exp. Med. (1998) 188:1641-1650.
30. SMITH CL, DULPHY N, SALIO M, CERUNDOLO V: Immunotherapy of colorectal cancer. Br. Med. Bull. (2002) 64:181-200.
31. GOYDOS JS, ELDER E, WHITESIDE TL, FINN OJ, LOTZE MT: A Phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res. (1996) 63:298-304. Clinical trial of peptide vaccine therapy for patients with colorectal cancer.
32. GONZALEZ G, CROMBET T, CATALA M et al.: A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial. Ann. Oncol. (1998) 9:431-435. Clinical trial of peptide vaccine therapy for patients with colorectal cancer.
33. SATO Y, MAEDA Y, SHOMURA H et al.: A Phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients. Br. J. Cancer (2004) 90:1334-1342. Clinical trial of peptide vaccine therapy for patients with colorectal cancer.
34. TSUDA N, MOCHIZUKI K, HARADA M et al.: Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers. J. Immunother. (2004) 27:60-72.
35. MOULTON HM, YOSHIHARA PH, MASON DH, IVERSEN PL, TRIOZZI PL: Active specific immunotherapy with a β-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival. Clin. Cancer Res. (2002) 8:2044-2051. Clinical trial of peptide vaccine therapy for patients with colorectal cancer.
36. MIYAGI Y, IMAI N, SASATOMI T et al.: Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin. Cancer Res. (2001) 7:3950-3962. Clinical trial of peptide vaccine therapy for patients with colorectal cancer.
37. ROSENBERG SA, YANG JC, SCHWARTZENTRUBER DJ et al.: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. (1998) 4:321-327.
38. NESTLE FO, ALIJAGIC S, GILLIET M et al.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. (1998) 4:328-332.
39. MARCHAND M, VAN BAREN N, WEYNANTS P et al.: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer (1999) 80:219-230.
40. WANG F, BADE E, KUNIYOSHI C et al.: Phase I trial of a MART-I peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin. Cancer Res. (1999) 5:2756-2765.
41. JAGER E, NAGATA Y, GNJATIC S et al.: Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc. Natl. Acad. Sci. USA (2000) 97:4760-4765.
42. HIROHASHI Y, TORIGOE T, MAEDA A et al.: An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin. Cancer Res. (2002) 8:1731-1739.
43. IDENOUE S, HIROHASHI Y, TORIGOE T et al.: A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin. Cancer Res. (2005) 15:1474-1482.
44. MOCELLIN S, MANDRUZZATO S, BRONTE V, MARINCOLA FM: Cancer vaccines: pessimism in check. Nat. Med. (2004) 10:1278-1279.
45. VALMORI D, DUTOIT V, AYYOUB M et al.: Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Cancer Immun. (2003) 3:15.
46. LETSCH A, KEILHOLZ U, FLUCK M et al.: Peptide vaccination after repeated resection of metastases can induce a prolonged relapse-free interval in melanoma patients. Int. J. Cancer (2005) 114(6):936-941. Clinical trial of adjuvant peptide vaccine therapy that induced a prolonged relapse-free interval.
47. VERMORKEN JB, CLAESSEN AM, VAN TINTEREN H et al.: Active specific immunotherapy for stage II and stage III human colon cancer. A randomized trial. Lancet (1999) 30:345-350. Clinical trial of adjuvant immunotherapy in surgically resected patients with an autologous tumour cell-BCG vaccine in colon cancer.
48. HOOVER HC, BRANDHORST JS, PETERS LC et al.: Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a Phase III prospectively randomized trial. J. Clin. Oncol. (1993) 11:390-399. Clinical trial of adjuvant immunotherapy in surgically resected patients with an autologous tumour cell-BCG vaccine in colon cancer.
49. HARRIS JE, RYAN L, HOOVER HC et al.: Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern cooperative oncology group study E5283. J. Clin. Oncol. (2000) 18:148-157. Clinical trial of adjuvant immunotherapy in surgically resected patients with an autologous tumour cell-BCG vaccine in colon cancer.
50. MITCHELL MS: Immunotherapy as part of combinations for the treatment of cancer. Int. Immunopharmacol. (2003) 3:1051-1059.